La complémentarité entre essais cliniques contrôlés et registres observationnels : L'exemple des études de prévention cardiovasculaire avec les inhibiteurs des SGLT2
Scheen, André; ERNEST, Philippe; JANDRAIN, Bernard
2017 • In Revue Médicale de Liège, 72 (12), p. 563-568
[en] Evidence-based medicine (EBM) is mainly supported by the results of randomised controlled trials (RCTs). If the latter offer guarantees of reliability, especially by minimizing the influence of confounding factors and potential biases, they also have limitations. Observational databases resulting from real life registries, if possible build in a prospective manner, may offer some solutions, but are also exposed to limitations. This article compares the advantages and disadvantages of the two sources of information, which ideally should be complementary. For the purpose of illustration, we shall compare the recent results of RCTs and of observational databases from multinational registries that investigated the effects of sodium-glucose cotransporter type 2 inhibitors (gliflozins) on cardiovascular outcomes in patients with type 2 diabetes.
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
ERNEST, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
JANDRAIN, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Language :
French
Title :
La complémentarité entre essais cliniques contrôlés et registres observationnels : L'exemple des études de prévention cardiovasculaire avec les inhibiteurs des SGLT2
Alternative titles :
[en] Complementarity between randomised controlled trials and observational registries : The example of cardiovascular prevention with SGLT 2 inhibitors
Scheen AJ.Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liege, 2000, 55, 216-219.
Scheen AJ.Comment j'explore . les secrets d'une méta-analyse. Rev Med Liege, 2003, 58, 41-46.
Ernest P, Jandrain B, Scheen AJ.Forces et faiblesses des essais cliniques : évolution en fonction de l'essor de la médecine personnalisée. Rev Med Liege, 2015, 70, 232-236.
Maisonneuve H, Babany G.Données de vie réelle et recherche clinique : le complément des données des essais randomisés Presse Med, 2015, 44, 586-589.
Vray M, Hamelin B, Jaillon P, et al. Place relative des essais cliniques comparatifs et des suivis de cohorte dans l'évaluation pré- et post-AMM des médicaments. Thérapie, 2005, 60, 339-344.
Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004, 364, 937-952.
Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J, 2006, 151, 786-110.
Zinman B, Wanner C, Lachin JM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373, 2117-2128.
Neal B, Perkovic V, Mahaffey KW, et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017, 377, 644-657.
Kosiborod M, Cavender MA, Fu AZ, et al.Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation, 2017, 136, 249-259.
Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucoselowering drugs (CVD-REAL Nordic) : A multinational observational analysis. Lancet Diabetes Endocrinol, 2017, 5, 709-717.
Persson F, Nystrom T, Jorgensen ME, et al.Dapagliflozin compared to DPP-4 inhibitors is associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetes patients (CVD-REAL Nordic) : A multinational observational study. Diabetes Obes Metab, 2017, Aug 3. doi: 10.1111/dom.13077. [Epub ahead of print].
Scheen AJ.Comment j'explore .Les critères de jugement dans les essais cliniques : réflexions à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liege, 2006, 61, 260-266.
Scheen AJ. EMPA-REG OUTCOME. L'empagliflozine réduit la mortalité chez le patient diabétique de type 2 à haut risque cardiovasculaire. Rev Med Liege, 2015, 70, 583-589.
Scheen AJ, Piérard L, Krzesinski J-M, et al.Protection cardiovasculaire et rénale du patient diabétique de type 2 : le point après EMPA-REG OUTCOME et LEADER. Rev Med Liege, 2016, 71, 376-381.
Scheen AJ, Ernest P, Jandrain B.Protection cardiorénale par les inhibiteurs des SGLT2 (gliflozines): d'EMPA-REG OUTCOME à CANVAS. Rev Med Suisse, 2017, 13, 1421-1426.
Arnold SV, Inzucchi SE, Tang F, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials : An NCDR(R) research to practice project. Eur J Prev Cardiol, 2017, 24, 1637-1645.
McGovern A, Feher M, Munro N, et al. Sodium- Glucose Co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use. Diabetes Ther, 2017, 8, 365-376.
Kaiser P, Arnold AM, Benkeser D, et al.Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort. Int J Epidemiol. 2017 Sep 8. doi:10.1093/ije/dyx179 [Epub ahead of print].
Raz I, Bonaca MP, Mosenzon O, et al.DECLARETIMI 58: design and baseline characteristics. Diabetes, 2017, 66, A333, Abstract 1245-P.
